Press release
Lyme Disease Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Lyme Disease Pipeline Outlook Report [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Lyme Disease Pipeline Report
* In December 2024, ModernaTX Inc . initiated a Phase 1/2 randomized, observer-blind, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of Heptavalent mRNA-1975 (SR1-7) and Monovalent mRNA-1982 (SR1) vaccines against Lyme disease in healthy participants aged 18 to 70 years.
* DelveInsight's Lyme Disease pipeline report depicts a robust space with 7+ active players working to develop 7+ pipeline therapies for Lyme Disease treatment.
* The leading Lyme Disease Companies such as Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics , and others.
* Promising Lyme Disease Therapies such as VLA15, mRNA-1975, Low Dose TP-05 and others.
Learn how leading Lyme Disease Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Lyme Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Lyme Disease Emerging Drugs
* VLA 15: Valneva
VLA15 is currently the only active vaccine program in clinical development against Lyme disease. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common pathogenic strains found in the United States and Europe. Valneva has completed recruitment and reported initial results for two Phase 2 clinical trials of VLA15 in over 800 healthy adults and in which Valneva observed high levels of antibodies against all six serotypes. Valneva announced a collaboration with Pfizer for late phase development and, if approved, commercialization of VLA15.
* CT38: Cortene
CT38 is a potent, short-lived, peptide agonist selective for CRFR2. It is comprised entirely of naturally-occurring amino acids. It was tested in animals and in healthy humans in a Phase 1 clinical trial. These studies have defined the safety profile of CT38 in humans and show that CT38 only lasts a few hours in the body.
The Lyme Disease pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Lyme Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lyme Disease Treatment.
* Lyme Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Lyme Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lyme Disease market.
From early-stage research to late-phase Lyme Disease Clinical Trials, our analysis covers key Lyme Disease Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Lyme Disease Treatment Drugs [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Lyme Disease Companies
Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics and others.
Lyme Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
Lyme Disease Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Stay updated with the latest Lyme Disease Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Lyme Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Lyme Disease Pipeline Report
* Coverage- Global
* Lyme Disease Companies- Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics , and others.
* Lyme Disease Therapies- VLA15, mRNA-1975, Low Dose TP-05 and others.
* Lyme Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Lyme Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Lyme Disease Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Lyme Disease Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Lyme Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Lyme Disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* VLA 15: Valneva
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CT 38: Cortene
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Lyme disease vaccine - Introvacc
* Drug profiles in the detailed report.....
* Inactive Products
* Lyme Disease Key Companies
* Lyme Disease Key Products
* Lyme Disease- Unmet Needs
* Lyme Disease- Market Drivers and Barriers
* Lyme Disease- Future Perspectives and Conclusion
* Lyme Disease Analyst Views
* Lyme Disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lyme-disease-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lyme Disease Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3902659 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Lyme
Lyme Disease Diagnostics Market Projected to Show Strong Growth
Advance Market Analytics published a new research publication on "Lyme Disease Diagnostics Market Insights, to 2033" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Lyme Disease Diagnostics market was mainly driven by the increasing R&D spending across the world.
Get Free Exclusive PDF Sample…
Lyme Disease - Drug Pipeline Landscape, 2022
Lyme disease is a tick-borne infection caused by four main species of bacteria Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii and Borrelia garinii. The disease is characterized by skin rash.
Early signs and symptoms of Lyme disease include rash and other symptoms like fever, chills, fatigue, body aches, and swollen lymph nodes. Later symptoms include erythema migrans, joint pain and other neurological problems.
To know more about Lyme Disease - Drug Pipeline ,…
Lyme Disease - Drug Pipeline Landscape, 2022 | Global Insight Services
Lyme disease is a tick-borne infection caused by four main species of bacteria Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii and Borrelia garinii. The disease is characterized by skin rash. Early signs and symptoms of Lyme disease include rash and other symptoms like fever, chills, fatigue, body aches, and swollen lymph nodes. Later symptoms include erythema migrans, joint pain and other neurological problems. Diagnosis of Lyme disease involves lab tests to…
Lyme Disease Vaccines - Are They Effective?| Valneva, GlaxoSmithKline Plc.
There is currently no Lyme disease vaccine available. LYMERix®, the only vaccine previously marketed in the United States, was withdrawn from the market in 2002 due to a lack of consumer demand. The vaccine's effectiveness deteriorates over time.
Lyme Disease Vaccines Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing…
Lyme Disease Therapeutics Market Size Statistics, Facts and Figures
Global Lyme Disease Therapeutics Market: Overview
Lyme disease is a contagious disease caused by a bacterium species called Borrelia burgdorferi. It is a tick-borne disease caused by transmission of bacteria to humans through the bite of infected ticks. Common indications of Lyme disease include flu-like symptoms, depression, fatigue, and expanding, circular, reddish skin rashes.
View Report : https://www.transparencymarketresearch.com/lyme-disease-therapeutics-market.html
If left untreated, these symptoms may worsen and can lead to partial or complete…
Lyme Disease Diagnostic Testing Market
The report presents a detailed analysis of the Lyme disease diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Lyme disease definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:
- Hospitals
- Commercial/Private Labs
…
